Zhitong Finance App News, Jinyao Pharmaceutical (600488.SH) issued an announcement. Recently, Jinyao Heping (Tianjin) Pharmaceutical Co., Ltd., a holding subsidiary of the company, participated in the 12th batch of centralized procurement of national drugs organized by the State Organization Pharmaceutical Joint Procurement Office. Compound potassium hydrogen phosphate injections are to be selected for this centralized procurement. The proposed price of the drug is 0.89 yuan/bottle. The procurement period starts from the date of implementation of the selection results to December 31, 2029.

According to reports, the 2025 sales revenue of the products to be selected was 11.4871 million yuan, accounting for 0.40% of the company's 2025 revenue; the sales revenue for the first quarter of 2026 was 915,700 yuan, accounting for 0.15% of the company's revenue for the first quarter of 2026. The selected price of the product to be selected this time has dropped to a certain extent compared to the original sales price. If selected, the procurement contract is signed and implemented, it will further expand sales of this product, increase market share, enhance the company's brand influence, and promote the further development of the company's formulation business.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.